Company intelligence / Profile preview

Phynova

Oxfordshire area, United Kingdomphynova.com ↗

Ownership: Private
Development stage: Commercial

Overview

Phynova’s lead product, Reducose®, is a patented plant-based functional ingredient shown in multiple human clinical trials to reduce post-meal blood glucose and insulin response by up to ~40% at a dose of about 250 mg. It has been tested extensively for safety and toxicity. The ingredient can be incorporated into foods, beverages, and supplements to lower glycemic index and support healthy blood sugar control.

Therapeutic areas: Metabolic DisordersEndocrinologyOther
Modalities: Plant-based natural extracts/ingredients for dietary supplements and functional foods/beveragesNo direct mention of small molecules, mAbs, or biologics; focus on botanical extracts and plant-powered ingredients
Industry: Food & Nutrition

Drug pipeline

1 asset

Reducose

Commercial

Indications: Blood glucose management

Beyond the preview

Go deeper on Phynova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phynova.

Explore the full profile